(NP (NP (NN Interaction)) (PP (IN of) (NP (DT the) (JJ human) (NN T-cell) (JJ lymphotropic) (NN virus) (NN type) (CD 1) (NN tax) (NN transactivator))) (PP (IN with) (NP (NN transcription) (NN factor) (NN IIA))) (. .))
(S (NP-SBJ (NP (DT The) (NN Tax) (NN protein)) (PP (IN of) (NP (NP (JJ human) (NN T-cell) (NN lymphotropic) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HTLV-1)) (-RRB- -RRB-))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ 40-kDa) (JJ transcriptional) (NN activator)) (SBAR (WHNP-31 (WDT which)) (S (NP-SBJ (-NONE- *T*-31)) (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (IN for) (NP-COOD (NP (NN HTLV-1) (NN gene) (NN regulation)) (CC and) (NP (JJ virus-induced) (JJ cellular) (NN transformation)))))))))) (. .))
(S (NP-SBJ-32 (NN Tax)) (VP (VBZ is) (VP (JJ localized) (NP (-NONE- *-32)) (PP (TO to) (NP (DT the) (NN DNA))) (PP (IN through) (NP (NP (PRP$ its) (NN interaction)) (PP (IN with) (NP (DT the) (JJ site-specific) (NNS activators) (NP-COOD (NP (ADJP (JJ cyclic) (JJ AMP-responsive) (JJ element-binding)) (NN protein)) (, ,) (NP (NN NF-kappaB)) (, ,) (CC and) (NP (NN serum) (NN response) (NN factor))))))))) (. .))
(S (NP-SBJ (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN recruitment)) (PP (IN of) (NP (NN Tax))) (PP (TO to) (NP (DT the) (NN DNA)))) (VP (VBZ positions) (NP (NN Tax)) (PP (IN for) (NP (NP (NN interaction)) (PP (IN with) (NP (DT the) (JJ basal) (JJ transcriptional) (NN machinery))))))))))) (. .))
(S (PP (IN On) (DT the) (NN basis) (IN of) (NP (JJ several) (JJ independent) (NNS assays))) (, ,) (NP-SBJ (PRP we)) (ADVP-TMP (RB now)) (VP (VBP report) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ physical)) (CC and) (ADJP (JJ functional))) (NN interaction)) (PP (IN between) (NP-COOD (NP (NN Tax)) (CC and) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN TFIIA))))))) (. .))
(S (ADVP (RB First)) (, ,) (NP-SBJ-33 (NN Tax)) (VP (VBD was) (VP (VBN found) (S (NP-SBJ (-NONE- *-33)) (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (ADJP (JJ 35-kDa) (PRN (-LRB- -LRB-) (NP (NN alpha)) (-RRB- -RRB-))) (NN subunit)) (PP (IN of) (NP (NN TFIIA))))) (PP (IN in) (NP (DT the) (NN yeast) (JJ two-hybrid) (NN interaction) (NN system)))))))) (. .))
(S (ADVP (RB Importantly)) (, ,) (NP-SBJ-34 (NP (CD two) (ADJP (RB previously) (VBN characterized)) (NNS mutants)) (PP (IN with) (NP (NN point) (NNS mutations))) (PP (IN in) (NP-COOD (NP (NN Tax)) (, ,) (NP (NP (NN M32)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Y196A)) (, ,) (NP (NN K197S))) (-RRB- -RRB-))) (CC and) (NP (NP (NN M41)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN H287A)) (, ,) (NP (NN P288S))) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP-35 (WDT which)) (S (NP-SBJ-36 (-NONE- *T*-35)) (VP (VBD were) (VP (VBN shown) (S (NP-SBJ (-NONE- *-36)) (VP (TO to) (VP (VB be) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (JJ Tax-activated) (NN transcription))))))))))) (VP (VBD were) (ADJP-PRD (JJ unable) (S (NP-SBJ (-NONE- *-34)) (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN TFIIA))) (PP (IN in) (NP (DT this) (NN assay)))))))) (. .))
(S (ADVP (RB Second)) (, ,) (NP-SBJ (DT a) (NP (NP (NN glutathione-S-transferase)) (PRN (-LRB- -LRB-) (NP (NN GST)) (-RRB- -RRB-))) (JJ affinity-binding) (NN assay)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN holo-TFIIA))) (PP (IN with) (NP (NN GST-Tax)))) (VP (VBD was) (ADJP-PRD (ADJP (RB 20-fold) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN observed) (NP (-NONE- *)) (PP (IN with) (NP-COOD (CC either) (NP (DT the) (NN GST-Tax) (NN M32) (NN activation) (NN mutant)) (CC or) (NP (DT the) (NN GST) (NN control)))))))))))) (. .))
(S (ADVP (RB Third)) (, ,) (NP-SBJ (DT a) (NN coimmunoprecipitation) (NN assay)) (VP (VBD showed) (SBAR (IN that) (S (PP (IN in) (NP (JJ HTLV-1-infected) (JJ human) (NN T) (NNS lymphocytes))) (, ,) (NP-SBJ-COOD-37 (NP (NN Tax)) (CC and) (NP (NN TFIIA))) (VP (VBD were) (VP (VBN associated) (NP (-NONE- *-37))))))) (. .))
(S (ADVP (RB Finally)) (, ,) (NP-SBJ (NN TFIIA)) (VP (NNS facilitates) (NP (NN Tax) (NN transactivation)) (ADVP-COOD (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))) (. .))
(S (NP-SBJ (ADJP (FW In) (FW vitro)) (NN transcription) (NNS studies)) (VP (VBD showed) (NP (NP (VBN reduced) (NNS levels)) (PP (IN of) (NP (JJ Tax-activated) (NN transcription))) (PP (IN in) (NP (NP (NN cell) (NNS extracts)) (VP (VBN depleted) (NP (-NONE- *)) (PP (IN of) (NP (NN TFIIA)))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (NN transfection)) (PP (IN of) (NP (JJ human) (NN T) (NNS lymphocytes))) (PP (IN with) (NP (NN TFIIA) (NN expression) (NNS vectors)))) (VP (VBD enhanced) (NP (NP (JJ Tax-activated) (NN transcription)) (PP (IN of) (NP (DT an) (ADJP (NN HTLV-1) (JJ long) (JJ terminal) (NN repeat-chloramphenicol) (NN acetyltransferase) (NN reporter)) (NN construct))))) (. .))
(S (NP-SBJ (PRP$ Our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN Tax))) (PP (IN with) (NP (DT the) (NN transcription) (NN factor) (NN TFIIA)))) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (JJ Tax-mediated) (JJ transcriptional) (NN activation)))))))) (. .))
